On November 30, during the G20 Summit in Buenos Aires Argentina, President Trump, Prime Minister Trudeau and President Peña Nieto signed the new U.S. Mexico Canada Agreement. Once approved by the U.S. Congress, this trade deal will replace NAFTA as the free trade agreement between the three North American countries.
At least one aspect of the treaty bodes well for patient access: Patent exclusivity will now last a minimum of 10 years for biologic medications. An extended period of patent exclusivity will encourage medical innovation, increasing patients’ access to more and better treatment options in various disease states.
This change marks an increase from Canada’s eight-year exclusivity period and Mexico’s five-year exclusivity period.
Recent Posts
Global Alliance for Patient Access
© 2024 GAfPA. All Rights Reserved
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |